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In 1956, Cruikshank described patients with spasticity (tropical spastic paraparesis, TSP) including a minority with ataxia (tropical ataxic neuropathy) which he termed Jamaican neuropathy. 2 In 1985 Gessain and colleagues, investigating the seroprevalence of human T cell lymphotropic virus type I (HTLV-I) among haematology patients in Martinique, chose neurology patients as controls and unexpectedly found that 59% of patients with tropical spastic paraparesis had anti-HTLV-I antibodies. 3 In Japan, where adult T cell leukaemia was first described in 1977 4 and associated with HTLV-I in 1981, 5 Osame et al independently described the association of HTLV-I with a spastic paraparesis which they called HTLV-I associated myelopathy (HAM). 6 While seronegative TSP has been described, 7 by definition all patients with HAM are infected with HTLV-I.
HTLV-I is a type C retrovirus, closely related to other human and primate lymphotropic viruses and the bovine leukaemia virus. Like all retroviruses the genome of HTLV-I contains GAG, POL, and ENV genes flanked by two long terminal repeats (LTR) which contain the transcription initiation sequences (Fig 1) . In addition, HTLV-I has another gene, pX with four open reading frames of which TAX and REX (the transactivating and regulating genes of the X region) have been best characterised. The protein product of the TAX gene is important not only for activating viral transcription but because it is able to transactivate a large number of human genes (Table 1) . For this reason TAX is considered to play a critical role in the development of adult T cell leukaemia/ lymphoma (ATLL). 8 No sequence diVerences distinguishing HTLV-I found in patients with HAM and patients with ATLL have been identified. 9 Like HIV-1, HTLV-I infects CD4 + T lymphocytes although CD4 is not the receptor. This has not yet been identified but has been localised to chromosome 17q and may be a member of the VCAM family. 10 The life cycle of HTLV-I is similar to other retroviruses. Infection requires interaction between the viral envelope and the cellular receptor following which the nuclear content is released into the cytoplasm and transported to the nucleus. The hallmark of a retrovirus is reverse transcription of viral RNA to produce proviral DNA which is then integrated into the cellular genome. In the case of HTLV-I integration occurs randomly. Following an unspecified period the proviral DNA is transcribed. Translation of spliced RNA produces the viral nucleocapsid proteins, enzymes, and envelope glycoproteins. The production of viral proteins is under the control of TAX and REX, with TAX upregulating transcription and REX exerting a negative feedback by reducing splicing of the precursor RNA which results in reduced production of viral proteins including TAX. The production of both full length viral RNA and the constituent proteins results in a new infectious virion which buds from the surface of the cell ready to infect a new target.
HTLVs are also able to replicate without use of reverse transcription which is error prone. Once integration has occurred transactivation of cellular genes results in cell proliferation and at each cell division a new copy of the integrated HTLV provirus is made. This HTLV-I and the related virus, HTLV-II, are transmitted by sexual intercourse, especially from males to females; parenterally through cellular blood products and the reuse of injecting equipment; and from mother to child, predominantly through breast feeding. Although Europe is not an endemic area for HTLV-I infection it is found among immigrants from high prevalence areas, their partners, and sporadically in the native population. HTLV-II is common among intravenous drug users in a number of European cities.
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Clinical and pathological features of HTLV-I associated myelopathy HAM/TSP is generally a slowly progressive disease; indeed patients often have had symptoms for years before diagnosis. The characteristic features are low back pain, urinary dysfunction, impotence, and spastic paraparesis. Remissions and relapses are not a feature, and the condition tends to plateau followed by stability or slow deterioration. With the average age at onset only 30-40 years and with up to 50% of patients becoming wheelchair dependent this is a disease of considerable morbidity. 13 Unlike Japan where the life time risk of a HTLV-I infected person developing HAM has been calculated to be 0.25% 14 HTLV-I carriers in the United Kingdom seem to have a much higher probability of HAM more similar to the 1.7-7% reported from Africa, 15 the Caribbean, 16 and the United States. 17 In addition to the characteristic clinical features, the diagnosis of HAM/TSP is made by excluding other pathology, particularly spinal cord compression, and confirming the presence of HTLV-I antibodies in serum and CSF. Computerised tomography is usually normal and magnetic resonance imaging may be normal or reveal high T2 weighted signal abnormalities in the white matter similar to those seen in multiple sclerosis. Although mild, there is evidence of inflammation in cerebrospinal fluid (Table 2 ) and cytokines may be implicated in pathogenesis.
At the postmortem examination of a 59 year old woman with HAM of 3 years' duration, who died of mixed mitral and aortic valve disease, Akizuki et al found proliferation of capillaries, perivascular cuYng with lymphocytes, loss of myelin and axons, proliferation of gemistocytic astrocytes, and infiltration with foamy macrophages. These changes were most severe in the lateral and anterior columns of the thoracic spinal cord but were also observed in the medulla, pons, and white matter of the cerebrum and cerebellum. They also found evidence of vasculitis and arachnoiditis with lymphocytic 19 After many years of HAM/TSP atrophy and gliosis, rather than inflammatory changes, predominate. 20 The clinical stability of patients with long standing HAM/TSP and this evolution of neuropathology have important implications when we come to consider the pathogenesis of HAM/TSP and responses to treatment.
Figure 2 Direct toxicity theory of HAM pathogenesis: HTLV-I infects glial cells which are lysed by cytotoxic T lymphocytes.
The lymphocytic infiltrate in patients with a short history of HAM/TSP is composed predominantly of CD4 + T cells. 21 Later the population is more mixed with both CD4 + and CD8 + lymphocytes and macrophages, with the production of interleukin-1 (IL-1 ), tumour necrosis factor-(TNF-), and interferon-(IFN-). In patients with long standing HAM/ TSP the infiltrate comprises predominantly CD8 + lymphocytes, and cytokine expression is rarely noted. 22 HTLV-I provirus can be found in the spinal cord; however, it remains uncertain whether HTLV-I infects astrocytes in vivo 23 or is only present in the cord within migrating lymphocytes. 24 
Pathogenesis of HTLV-I associated myelopathy
In cross sectional studies HTLV-I proviral load has been found to be at least 10-fold higher in patients with HAM/TSP than in carriers although the ranges of proviral load overlap. In patients with TSP/HAM this viral burden was relatively constant over several months. 25 In a prospective study HTLV-I proviral load, whether high or low, remained relatively constant over 2-3 years in most patients and carriers. Multiple measurements of proviral load in a carrier who developed HAM revealed a constant high proviral load, more than the average for a patient with HAM, that predated by at least 2.5 years the onset of symptoms. 26 Jacobson et al reported that HTLV-I specific cytotoxic T lymphocytes (CTL) were present in patients with HAM/TSP but not in carriers, 26 but Parker et al found anti-HTLV-I specific CTL in carriers and in HAM/TSP. 27 The immunodominant peptides are invariably found in the TAX protein. Recently, Biddeson et al reported that anti-TAX specific CD8 + CTL produce a variety of cytokines which may be implicated in the pathogenesis of HAM/ TSP (Table 3) . 28 In particular, TNF-and IFN-are associated with demyelination.
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Pathogenesis hypotheses
There are three main hypotheses; direct toxicity, autoimmunity, and bystander damage. 30 In the first hypothesis it is presumed that HTLV-I infects glial cells in vivo, which then present HTLV-I antigens on their cell surface. Circulating CD8 + cytotoxic T cells specific for a HTLV-I antigen cross the blood-brain barrier, encounter the infected cell, and release cytokines which cause cell death (Fig 2) .
The second hypotheses presumes that a glial cell "self " antigen is similar to a viral antigen. CD4 + helper cells encounter this viral antigen in the periphery and upon crossing the bloodbrain barrier, mistake the glial cell for an infected cell triggering autoimmune activity with death of the glial cell. Alternatively, CD4 + "helper" cells which by chance recognise "self " antigen are stimulated to proliferate by infection with HTLV-I. The chance of infection of such a cell would be related to the infectious burden of virus (Fig 3) . In the third hypothesis, HTLV-I infected CD4 + and anti-HTLV-I specific CD8 + lymphocytes migrate across the blood-brain barrier, meet in the CNS and the innocent glial cells are damaged by cytokines released against the infected lymphocyte (Fig  4) . While there are few in vivo data to support the first hypothesis, either or both of the others may play a role in the pathogenesis.
Treatment of HTLV-I associated myelopathy
A summary of reports of the treatment of HAM is presented in Table 4 . Most treatments have been directed at reducing inflammation in the aVected tissues either directly, as with corticosteroids, or indirectly-for example, heparin, while interferon-has both antiviral and immunomodulatory capacity. The only published studies of specific antiretroviral therapy are of zidovudine and lamivudine. With a single exception all reports have been of open preliminary studies, limited by small numbers of patients and the possibility of placebo eVect. Earlier studies used HTLV-I antibody titres (or in one case the numbers of atypical lymphocytes) as a surrogate for proviral load and focused on spontaneous lymphocyte proliferation (an ex vivo phenomenon) and T cell subsets to measure change in the immune response. In a number of studies both treatment and follow up have been of short duration and longer studies of the same treatment modality have been less encouraging. Thus, Matsuo et al reported a rapid but transient improvement with plasmapheresis for 14 days 31 but approximately 2 years later none of their patients were improved and 6/18 had deteriorated. 32 Similarly, although Osame et al reported improvement in 58 of 65 patients treated with high dose prednisolone, 33 symptoms often worsen again as the dose is reduced, and Kira et al reported that 33% of their patients had further deteriorated from baseline during 20-33 months of follow up. 36 Nakagawa et al observed that while 69.5% of 131 patients had an excellent or moderate response to oral prednisolone, the benefits were transient and the complications of steroids would limit their use particularly in post-menopausal females for whom interferonmight be more appropriate. 47 The steroid responsiveness of HAM has not been confirmed outside Japan. There have been several favourable reports relating to short duration therapy with interferon-. 34 38 40 45 46 ore significantly, Yamasaki et al recently reported clinical, immunological, and virological improvement when treatment was continued for 6 months. 48 Although the reduction in proviral load was modest this is the first treatment study to report HTLV-I proviral load measurements and is at variance with previous studies which concluded that interferon-did not have any anti-HTLV-I eVect because the anti-HTLV-I antibody titres did not change. However, this study, like those using steroid sparing cytotoxics 33 43 and the anabolic steroid danazol, 37 is limited by small numbers and its open nature. The limited nature of the benefits of treatments such as interferon-and plasmapheresis is indicated by the following comment from the Nagasaki group. Referring to their earlier studies they conclude that "these modalities are . . . plagued with problems of high cost and the high frequency of side eVects." 41 In 1992 this group reported that the adherence of T cells to endothelial cells ex vivo was significantly increased in patients with HAM compared with controls. 49 Although they initially tried daily intravenous infusions of heparin in HAM 41 they have recently suggested that oral pentoxifylline may, by reducing the migration of activated T lymphocytes across the blood-brain barrier, be a safe and beneficial treatment. 46 Gout et al treated five patients with HAM with zidovudine and concluded that they did not get worse. Their patients had long standing disease and no measurement of viral burden was made. 39 Sheremata et al treated 10 patients with HAM with zidovudine and reported improved mobility in some. They did not report proviral load measurements because both HTLV-I and globin DNA were reduced in their patients' peripheral blood during treatment. 42 Recently five patients with HAM/ TSP and high proviral load were treated with lamivudine monotherapy. The median proviral load reduction during 6 months of therapy was greater than 1 log 10 although by 6 months proviral load had returned to baseline in three subjects. In the only patient with recent onset of symptoms clinical improvement was associated with a reduction in anti-TAX CTL frequency which fell with the decline in proviral load. 50 Clinical benefits in up to 50% of patients have been reported with a variety of other agents including the antibiotics erythromycin and fosfomycin, which may have immunomodulating eVects, as well as agents used in inflammatory disease such as salazosulphapyridine. The transient nature of the benefits in many of these open studies and the wide range of therapies which have given similar results suggests that a placebo response may be contributing to the positive findings. However, since the majority of patients participating in these studies have had symptoms of HAM for many years, sometimes decades, and are likely to have a considerable degree of irreversible neurological damage, failure to produce significant permanent improvement does not necessarily imply that these treatments are inappropriate for all patients with HAM/TSP. Future studies should aim to include patients with more recent onset of symptoms as well as those who are progressing and should include direct measurement of viral burden as well as the immune response.
Summary
That HTLV-I is not a latent infection is indicated by the detection of mRNA in the peripheral blood and CNS of patients with HTLV-I infection and by the persisting humoral and cellular immune responses. Indeed the frequency of anti-HTLV CTL is extremely high. The reduction in anti-TAX CTL frequency following reduction in proviral load suggests that removal of viral antigen may result in a reduced inflammatory response at least in peripheral blood and although the clinical data should be interpreted with caution, perhaps in the CNS. Patients with more advanced disease, and possibly fixed deficits may not benefit from either anti-inflammatory or antiretroviral treatment. The patients with most to gain are those with least deficit in whom early diagnosis and treatment will depend on raising awareness of HTLV-I beyond the neurological community. Many patients with HAM first present to a urologist or gynaecologist with bladder dysfunction or may have been seen in the genitourinary clinical with impotence or positive treponemal serology, which in the older patient is often the result of childhood infection with Treponema pallidum pertenue. Investigation of these patients should include HTLV-I serology and further investigation of HTLV-I positive patients should include proviral load measurements as well as markers of inflammation. Treatments whether antiviral or antiinflammatory should be assessed for their eVect on both as well as a clinical response. Describes the interaction between HTLV-I and host cell proteins particularly the eVects of Tax.
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